# Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS

> **NCT01668654** · PHASE3 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 4 (actual)

## Conditions studied

- Epilepsy

## Interventions

- **DRUG:** retigabine/ezogabine

## Key facts

- **NCT ID:** NCT01668654
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-09-04
- **Primary completion:** 2013-06-18
- **Final completion:** 2013-06-18
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** FDA placed a clinical hold on the Pediatric Program requiring retigabine discontinuation in subjects; early termination allows for timely reporting of results.
- **Last updated:** 2020-10-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01668654

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01668654, "Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01668654. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*